摘要
目的:观察西地兰治疗心力衰竭的临床观有效性及安全性。方法:32例心力衰竭患者平分为两组-美托洛尔组和西地兰组,分别采用上述两种药物治疗。结果:在各个重复治疗观察点,西地兰组均较美托洛尔组有更高的有效率,两组相比有显著性差异(P<0.05)。西地兰组平均起效时间13.1±7.5分钟;美托洛尔平均起效时间13.5±8.5分钟,两组起效时间比较有显著性差异(P<0.05)。两组不良反应相比无显著性差异(P>0.05)。结论:静脉应用西地兰能有效安全地提高心力衰竭的有效率,起效快,安全。
Objective：To observe clinical effectiveness and safety of cedilanid in treatment of cardiac failure. Method：Equally divide 32 patients with cardiac failure into two groups-a metoprolol group and a cedilarlid group ;then adopt the two said medicines above to treat the patients respectively. Result ： In watchpoints of repeated treatments, the cedilanid group is more efficient than the metoprolol group, and there is distinctive difference in the two groups （ P 〈 0. 05 ）. The cedilanid group＇s average onset time is （ 13.1 ± 7. 5 ） minutes ; the metoprolol group＇ s average onset time is （ 13.5± 8.5 ） minutes; there is distinctive difference in the two groups ＇average onset time （ P 〈 0. 05 ）. There is no distinctive difference in the two groupslanwanted effect （ P 〉 0. 05 ）. Conclusion： Application of intravenous cedilanid can effectively and safely enhance the effectiveness of cardiac failure, whose quick effect and safety are worth promoting in application.
